“Genomic variations between fibrolamellar and conventional hepatocellular carcinomas: implications for targeted therapy”

https://pubmed.ncbi.nlm.nih.gov/38116022

This study found distinct genomic variations between fibrolamellar hepatocellular carcinoma (FL-HCC) and conventional hepatocellular carcinoma (HCC), with TP53 and CTNNB1 mutations being common in HCC and DNAJB1 fusion uniquely identified in FL-HCC, highlighting the potential for targeted therapeutic approaches based on these genetic differences.